Oregon Public Employees Retirement Fund Acquires 4,135 Shares of ResMed Inc. $RMD

Oregon Public Employees Retirement Fund boosted its holdings in shares of ResMed Inc. (NYSE:RMD) by 32.8% in the third quarter, Holdings Channel.com reports. The fund owned 16,735 shares of the medical equipment provider’s stock after buying an additional 4,135 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in ResMed were worth $4,581,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in RMD. Johnson Investment Counsel Inc. boosted its position in shares of ResMed by 2.8% in the 2nd quarter. Johnson Investment Counsel Inc. now owns 1,665 shares of the medical equipment provider’s stock worth $430,000 after purchasing an additional 45 shares during the last quarter. Quadcap Wealth Management LLC lifted its stake in ResMed by 2.5% in the second quarter. Quadcap Wealth Management LLC now owns 1,880 shares of the medical equipment provider’s stock valued at $485,000 after buying an additional 45 shares during the period. OFI Invest Asset Management lifted its stake in ResMed by 10.4% in the third quarter. OFI Invest Asset Management now owns 509 shares of the medical equipment provider’s stock valued at $139,000 after buying an additional 48 shares during the period. V Square Quantitative Management LLC boosted its holdings in ResMed by 3.0% during the second quarter. V Square Quantitative Management LLC now owns 1,747 shares of the medical equipment provider’s stock worth $451,000 after buying an additional 51 shares during the last quarter. Finally, Miracle Mile Advisors LLC grew its position in shares of ResMed by 4.9% during the 3rd quarter. Miracle Mile Advisors LLC now owns 1,150 shares of the medical equipment provider’s stock worth $315,000 after buying an additional 54 shares during the period. Institutional investors and hedge funds own 54.98% of the company’s stock.

Key Headlines Impacting ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Zacks Research raised multiple near‑term and multi‑year EPS forecasts for RMD (modest bumps to quarterly forecasts and lifts to FY2026–FY2028: FY2026 to $10.62, FY2027 to $11.20 and FY2028 to $12.80). Upgrades signal stronger expected revenue/margin momentum and are a clear catalyst for buying interest. Zacks Upgrades
• Positive Sentiment: Large institutional activity (e.g., Norges Bank new stake and other funds materially increasing positions) supports conviction from long‑term investors and can underpin further accumulation ahead of earnings. Institutional Ownership
• Neutral Sentiment: ResMed set its Q2 FY2026 earnings release for Jan. 29 (after the close) with a webcast — a near‑term event that can amplify moves depending on results and guidance. Earnings Date
• Neutral Sentiment: Consensus remains constructive (MarketBeat shows a “Moderate Buy” with an average target ~ $296). That positive analyst backdrop supports buying but leaves limited room if guidance disappoints. Analyst Consensus
• Negative Sentiment: Insider selling: CEO Michael J. Farrell sold ~4,991 shares (~$248.46 avg) and Director Peter C. Farrell sold 2,000 shares (~$248.83 avg) on Jan. 7. While both retain large stakes, disclosed sales can create short‑term nervousness and are being watched by investors. SEC filings: CEO Form 4 and Director Form 4

ResMed Stock Up 0.6%

ResMed stock opened at $252.47 on Friday. The company has a 50 day moving average of $248.44 and a 200-day moving average of $263.21. The company has a quick ratio of 2.13, a current ratio of 2.89 and a debt-to-equity ratio of 0.07. ResMed Inc. has a twelve month low of $199.92 and a twelve month high of $293.81. The stock has a market capitalization of $36.84 billion, a PE ratio of 25.84, a price-to-earnings-growth ratio of 1.70 and a beta of 0.88.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Friday, October 31st. The medical equipment provider reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. The business had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.33 billion. ResMed had a net margin of 27.35% and a return on equity of 25.45%. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period last year, the business posted $2.20 earnings per share. On average, equities research analysts anticipate that ResMed Inc. will post 9.47 EPS for the current fiscal year.

ResMed Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, December 18th. Stockholders of record on Thursday, November 13th were issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date was Thursday, November 13th. ResMed’s payout ratio is 24.56%.

Analysts Set New Price Targets

A number of analysts recently weighed in on RMD shares. KeyCorp increased their price target on shares of ResMed from $298.00 to $299.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Baird R W cut shares of ResMed from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 16th. UBS Group reissued a “buy” rating and issued a $345.00 price target on shares of ResMed in a report on Friday, December 12th. Mizuho dropped their price objective on ResMed from $310.00 to $300.00 and set an “outperform” rating on the stock in a research note on Friday, October 31st. Finally, Wells Fargo & Company initiated coverage on ResMed in a report on Monday, October 13th. They set an “equal weight” rating and a $280.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $296.09.

Insider Activity

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $248.83, for a total value of $497,660.00. Following the sale, the director owned 66,773 shares in the company, valued at approximately $16,615,125.59. The trade was a 2.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Witte Jan De sold 2,055 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $255.00, for a total value of $524,025.00. Following the transaction, the director directly owned 4,261 shares of the company’s stock, valued at approximately $1,086,555. This trade represents a 32.54% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 21,594 shares of company stock worth $5,403,495 over the last three months. Corporate insiders own 0.65% of the company’s stock.

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.